Estrogen Receptor Beta in Breast Cancer of BRCA1 Mutation Carriers
Author Information
Author(s): Litwiniuk Maria M, Rożnowski Krzysztof, Filas Violetta, Godlewski Dariusz D, Stawicka Małgorzata, Kaleta Remigiusz, Bręborowicz Jan
Primary Institution: Poznan University of Medical Sciences
Hypothesis
What is the role of estrogen receptor beta (ERβ) in hereditary breast cancer among BRCA1 mutation carriers?
Conclusion
BRCA1-associated tumors show significantly higher expression of ERβ compared to ERα, which may explain the effectiveness of tamoxifen in preventing contralateral breast cancer in these patients.
Supporting Evidence
- Only 14.5% of BRCA1-related cancers were ERα-positive compared to 57.5% in the control group.
- 42% of BRCA1-related tumors expressed ERβ, while 55% of the control group did.
- 75% of hereditary cancers were found to be triple-negative.
Takeaway
This study found that women with a BRCA1 mutation have a different type of breast cancer that often doesn't have the usual estrogen receptors, but they do have another type called ERβ, which might help explain why a certain medicine works for them.
Methodology
The study involved 48 women with confirmed BRCA1 mutations and a control group of 120 breast cancer patients, using immunostaining to assess receptor expression.
Potential Biases
Potential selection bias in the control group as not all were tested for BRCA1 mutations.
Limitations
The study's findings may not be generalizable beyond the Polish population due to the specific mutations studied.
Participant Demographics
The average age of BRCA1 mutation carriers was 45 years, while the control group averaged 57 years.
Statistical Information
P-Value
<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website